The humerus is the second most common site of metastatic bone disease involving long bones.
Since from the end of the 1980s, lung carcinoma was suggested to be the most commonly causative histotype of metastatic bone disease from occult primaries [2, 5, 11, 19, 20, 21].
Zoledronic acid is the most widely used bisphosphonate for metastatic bone disease and osteoporosis because of its relative higher potency and short infusion time.
Although urinary Ntx has proved to be one of the most responsive bone markers in metastatic bone disease and results from the present study are encouraging, it would be desirable to study the relationship between skeletal events and other urine and serum bone markers.
Most of the clinical problems associated with metastatic bone diseases are a result of tumor-induced dysregulation of abnormal bone turnover.
It appears to be one of the most potentially useful of these markers in metastatic bone disease (Lipton et al, 2001).
68 Metastatic bone disease is one of the most common metastases in breast cancer.
Although iNOS has been studied extensively in most primary tumours, there are no reports that have investigated its expression in metastatic bone disease.
The most common causes of hypercalcemia, hyperparathyrodism, parathyroid hormone-related peptide secretion from tumour cells, and metastatic bone disease, were all dismissed as the etiology.
Most studies focused on the development of skeletal related events (SREs) and the quality of life of patients with metastatic bone disease [ 11].
